Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

May

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention

Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer

ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial

Behind the Scenes of the 2026 ASCO Annual Meeting